May 01, 2026

NEI Director Highlights Opportunities for Vision Research

At a time when federal research funding is under close scrutiny, leaders at the National Eye Institute (NEI) are emphasizing continuity, opportunity, and the outsized role of vision science within the broader research ecosystem. Speaking to a packed audience at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, NEI Director Michael F. Chiang, MD, framed recent policy and budget shifts as an evolution in how research is supported.

Retinal Physician

May 01, 2026

Philadelphia Institutions Launch Glaucoma Research Retreat

Researchers from 5 institutions met to discuss neuroprotection, diagnostics, gene therapy, and regional collaboration.

Glaucoma Physician

May 01, 2026

Clinical Trial Update May/June 2026

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

Retinal Physician

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 20, 2026

Amoxicillin-Clavulanate vs Amoxicillin for Sinusitis

Amoxicillin-clavulanate was not linked to lower treatment failure but was associated with a slightly higher risk of secondary infections compared with amoxicillin in adults with uncomplicated acute sinusitis.

Conexiant

April 17, 2026

Radiology Groups Push Back on New Cancer Screening Guidelines

Radiology groups say the ACP's new screening recommendations conflict with nearly every major cancer organization and could cost thousands of lives annually.

Conexiant

April 17, 2026

ACP Updates Breast Cancer Screening Guidance

Biennial mammography recommended for ages 50 to 74 years, with shared decision-making outside that range.

Conexiant

April 17, 2026

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Conexiant

April 17, 2026

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

The ASCO Post

April 17, 2026

Incretin Trials Often Exceed Muscle-Loss Benchmarks

Systematic review finds muscle-related losses frequently surpass expected thresholds during weight loss, though clinical impact remains unclear

Conexiant